Cyprotex PLC, a specialist ADME-Tox contract research organization, has acquired the business and assets of CeeTox Inc., a division of North American Science Associates Inc.
CeeTox, based in Kalamazoo, Mich., specializes in the provision of in vitro toxicological assays and screening data, principally to the cosmetic and personal care industries. CeeTox was acquired in 2005 by NAMSA, a medical research organization supplying expert consulting, clinical, and laboratory services to medical device, IVD, and biologics manufacturers. NAMSA retains a license for applying CeeTox’s in vitro toxicology expertise to medical device testing.
It is expected that Cyprotex will continue to operate the CeeTox business from its Kalamazoo location for a period of time prior to relocation of the business and assets to Cyprotex’s U.S. base in Watertown, Mass.
“The acquisition of CeeTox and its world-respected in vitro toxicology assays affords Cyprotex the opportunity to grow revenues significantly. Principally, it enables the company to offer a more complete assay and screening service to the cosmetics and personal care industry, already an expanding customer segment, and will materially extend the company’s footprint in its established core pharmaceutical and agrochemical industry markets,” says Dr. Anthony Baxter, CEO of Cyprotex.
“The innovative assays and screens that CeeTox has developed over its 10-year life are complementary to our existing comprehensive platform. In particular, we are excited by the potential for selling the Endocrine Disruptor Screening Program (EDSP) service to both current government agency customers and to industrial chemical companies.”
“We are delighted that, in acquiring the CeeTox business, Cyprotex is committed to both maintaining our reputation for innovative high quality science and to growing our existing customer base,” says Tim Mitchell, CEO of CeeTox. “The combination of our two businesses represents an outstanding opportunity to leverage our capabilities and capitalize on the enormous market potential across a variety of industries that require in vitro toxicity screening services.”
Cyprotex is based in Macclesfield, near Manchester in the U.K., and Watertown, Mass. in the U.S. It provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include in vitro ADME screening services, mechanistic toxicology, and high content toxicology screening services.
Release Date: January 2, 2014
Source: Cyprotex
